I carried out my PhD. studies in Oslo at Prof. Philippe Collas¿ lab, where I have focused in understanding how interactions between chromatin-associated and nuclear envelope (NE) proteins can affect cell cycle progression and DNA replication. During these studies, and taking advantage of a large number of biochemical and fluorescent microscope techniques, I show that disruption of chromatin/NE interactions affects NE breakdown and chromatin condensation at the beginning of mitosis and may prevent initiation of DNA replication due to degradation of Cdc6, a component of the pre-replication complex. After finishing my PhD studies, in 2004, I decided to move to a new research area, as a PosDoc in Prof. Carmo-Fonseca´s lab, where I started by being particularly interested in understanding how splicing affects transcription dynamics using a combination of live-cell imaging, chromatin immunoprecipitation and quantitative real-time PCR approaches. From these studies, I identified a novel link between spliceosome assembly and transcription termination, showing that inhibition of early spliceosome assembly leads to abortive transcription at the 3 ´end region of human genes. In the past few years, and taking advantage of my already solid research experience, I started developing new methodologies capable of being applied in the management of human genetic disorders, namely familial cardiomyopathies (HCM and DCM). In particular, in our lab, I was responsible for the implementation of protocols for gene editing of mammalian cells using the CRISPR/cas9 system, a powerful tool for targeted genome engineering. So, we started by established proof-of-principle for editing the murine TNNT2 gene in both embryonic stem cells and HL-1 mouse cardiomyocytes. The TNNT2 gene that codes for sarcomeric Troponin T, is one of the most frequently mutated gene in familial cardiomyopathies, and a cluster of mutations is present in its exon8. So, here, we managed to target a therapeutic, wild type, TNNT2 cDNA (exon7-exon15) preceded by a splice acceptor site into the intron6 of TNNT2. This allowed for splicing of a wild-type coding sequence with the previous exon6, leading to expression of a wild-type TNNT2 protein and correcting any TNNT2 mutation downstream of exon6. (FCT funded project, Exploring new therapeutic approaches for Hypertrophic Cardiomyopathy, EXPL/BIM­MEC/0201/2013, PI: Sandra Martins). At the moment, we are combining gene editing and human myocardium engineering for precision cardiology. Investigating the cellular and molecular pathways disrupted by mutations that cause hypertrophic familial cardiomyopathy (HCM) may provide novel insight into compensatory forms of cardiac remodelling triggered by more common diseases. We are hypothesizing that despite genetic diversity, mutations causing either HCM induce a common adaptive cellular response, with specific gene expression signatures, irrespective of the genetic defect in the myosin motor. To address this view we intend to investigate global transcriptomic and proteomic profiles linked to disrupted sarcomerogenesis caused by HCM mutations in heart tissue engineered in vitro from iPSC-derived cardiomyocytes. To avoid background genetic differences in patient iPSCs, we are using the recently reported CRISPR-Cas9 strategy to selective introduction of isogenic cell lines harbouring well characterised HCM-causing mutations. Using single-cell transcriptomics we will resolve the inherent heterogeneity and asynchronous nature of iPSC maturation. We will further use direct RNA sequencing technologies to obtain unprecedented information on alternative splicing isoforms and different levels of transcripts. W e expect our results will contribute to the identification of novel biomarkers and potential therapeutic targets in cardiac disease.